Retracted: A Spotlight on Friedreich Ataxia: Optimising the Patient Journey from Diagnosis to Disease Management

Chairperson:

Sylvia Boesch^1,2

Speakers:

Mathieu Anheim,³ Paola Giunti⁴

1. Department of Neurology, Medical University of Innsbruck, Austria
2. Centre for Rare Movement Disorders, Innsbruck, Austria
3. Movement Disorders Unit, University Hospital of Strasbourg, France
4. Department of Clinical and Movement Neurosciences, University College London Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, UK

Disclosure:

Anheim has received sponsorship from Reata Pharmaceuticals; and honoraria from AbbVie, Aguettant, Asdia, EVER Pharma, Ipsen, Merz Pharma, ORKYN’, Reata Pharmaceuticals, and
Teva Pharmaceuticals. Boesch has received fees for consultancy, advisory boards, and/or honoraria from AbbVie, Ipsen, Reata Pharmaceuticals, Merz Pharma, Stada Arzneimittel, and VICO Therapeutics. Giunti has received grants and consultancy fees from Reata Pharmaceuticals and VICO Therapeutics; and consultancy fees from Triplet Therapeutics and PTC Therapeutics.

Acknowledgements:

Writing assistance was provided by Nicola Humphry, Nottingham, UK.

Support:

The publication of this article was funded by Reata Pharmaceuticals. The views and opinions expressed are exclusively those of the speakers.

Citation:

EMJ Neurol. 2023;11[1]:35-42. DOI/10.33590/emjneurol/10301016. https://doi.org/10.33590/emjneurol/10301016.

Keywords:

Friedreich ataxia (FA), ataxia, rare disease, neurodegenerative disease.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.